Sitagliptin is an oral medication indicated for type 2 diabetes mellitus (T2DM) and prevents inactivation of GLP-1 by selectively inhibiting DPP-4, thus increasing insulin secretion and decreasing glucagon concentration in a glucose-dependent manner [1, 4]. This evidence concerns the gene INS and type 2 diabetes mellitus.